U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8BrNO2
Molecular Weight 218.048
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROCRESINE

SMILES

NOCC1=CC=C(Br)C(O)=C1

InChI

InChIKey=QNWOSJAGFSUDFE-UHFFFAOYSA-N
InChI=1S/C7H8BrNO2/c8-6-2-1-5(4-11-9)3-7(6)10/h1-3,10H,4,9H2

HIDE SMILES / InChI

Description

Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease.

CNS Activity

CNS Active
4,002

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Histidine decarboxylase
9
Inhibitor
8,504
 10.0 nM [IC50]
Aromatic-L-amino-acid decarboxylase
5
Inhibitor
8,504
 500.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Parkinson's disease
232
 Secondary
Phase I
438
Unknown

Doses

AEs

PubMed

Patents

US3651236
1
US9757456
1

Sample Use Guides

In Vivo Use Guide
With the dose given (200 mg/kg i.p.) brocresine caused inhibition of gastric histidine decarboxylase activity in both normal and vagally denervated rats.
Route of Administration: Intraperitoneal
In Vitro Use Guide
Tyrosine hydroxylase activity was assessed by incubation of hypothalamic cells for 1 h with 100 uM brocresine, an inhibitor of aromatic L-amino acid decarboxylase.
ACTIVE MOIETY
Structure of BROCRESINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966